In vivo efficacy of beta-cyclodextrin derivatives against anthrax lethal toxin.
We evaluated the in vivo efficacy of three beta-cyclodextrin derivatives that block the anthrax protective antigen pore. These compounds were at least 15-fold more potent than previously described beta-cyclodextrins in protecting against anthrax lethal toxin in a rat model. One of the drugs was shown to protect mice from bacterial infection.
Moayeri
Mahtab
M
Bacterial Toxins and Therapeutics Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.
Robinson
Tanisha M
TM
Leppla
Stephen H
SH
Karginov
Vladimir A
VA
D000818:Animals; D000881:Anthrax / Q000188:drug therapy* / Q000401:mortality / Q000517:prevention & control*; D000942:Antigens, Bacterial / Q000378:metabolism; D001408:Bacillus anthracis / Q000187:drug effects / Q000472:pathogenicity*; D001427:Bacterial Toxins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D004195:Disease Models, Animal; D051379:Mice; D016896:Treatment Outcome; D047392:beta-Cyclodextrins / Q000737:chemistry* / Q000494:pharmacology*
D000942:Antigens, Bacterial; D001427:Bacterial Toxins; C030325:anthrax toxin; D047392:beta-Cyclodextrins